Semaglutida e Tirzepatida: efeitos dos agonistas GLP-1/GIP na microbiota intestinal e potencial associação com SIBO.
Revista ft · 21.05.2026 · 30 (158) · 01-25
DOI: 10.69849/7wmx9h50 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista ft, online erschienen am 21.05.2026. Verfasst von Lara Ferreira dos Reis und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity and type 2 diabetes mellitus represent significant global public health challenges, driving the development of incretin-based therapies, such as GLP-1 receptor agonists and GLP-1/GIP coagonists, including semaglutide and tirrizepatide. These medications demonstrate significant efficacy in glycemic control, weight reduction, and metabolic improvement, mainly by promoting increased glucose-dependent insulin flexibility, reduced glucagon, delayed gastric emptying, and increased satiety. However, these therapeutic effects on gastrointestinal motility have aroused increasing interest due to the possibility of repercussions on the gut microbiota and the development of small intestinal bacterial overgrowth (SIBO). This study aimed to analyze the possible relationship between the use of semaglutide and tirzepatide and the development of SIBO, considering their effects on gastrointestinal motility and the gut microbiota. This is a systematic literature review, with a qualitative and descriptive approach, conducted according to PRISMA recommendations. The bibliographic search was conducted in national and international databases, including PubMed/MEDLINE, NCBI, SciELO, BVS, and Google Scholar, encompassing publications between 2017 and 2026. Studies related to incretin physiology, the mechanisms of action of semaglutide and tirzepatide, the gastrointestinal effects of these therapies, alterations in the gut microbiota, and factors associated with the development of SIBO were included. The analysis of the studies demonstrated that GLP-1/GIP agonists exert important effects on the gastrointestinal tract, especially by slowing intestinal transit and modulating gastric emptying. These alterations can favor luminal stasis, excessive bacterial fermentation, and intestinal microbiota imbalance, creating pathophysiological conditions potentially associated with the development of SIBO in susceptible individuals. Despite the biological plausibility of this association, current evidence remains predominantly indirect and observational, making it impossible to establish a definitive causal relationship between the use of these therapies and the development of SIBO. It is concluded that semaglutide and tirzepatide represent effective and promising therapies in the management of obesity and type 2 diabetes mellitus; however, important gaps remain regarding their gastrointestinal effects and possible impact on the intestinal microbiota. Therefore, more robust prospective and clinical studies are needed for a better understanding of this possible association and for the development of safer monitoring strategies during the use of these medications.
Zitieren
APA
Reis, L. F. D., Yvamoto, É. Y., Jesus, L. B. F. D., Saraiva, H. P., & Oliveira, É. S. (2026). Semaglutida e Tirzepatida: efeitos dos agonistas GLP-1/GIP na microbiota intestinal e potencial associação com SIBO. Revista ft, 30(158), 01-25. https://doi.org/10.69849/7wmx9h50
Vancouver
Reis LFD, Yvamoto ÉY, Jesus LBFD, Saraiva HP, Oliveira ÉS. Semaglutida e Tirzepatida: efeitos dos agonistas GLP-1/GIP na microbiota intestinal e potencial associação com SIBO. Revista ft. 2026;30(158):01-25. doi:10.69849/7wmx9h50
BibTeX
@article{Reis2026,
author = {Reis, Lara Ferreira dos and Yvamoto, Érika Yuki and Jesus, Laura Barroco Fontes de and Saraiva, Hannah Pereira and Oliveira, Évelin Santos},
title = {Semaglutida e Tirzepatida: efeitos dos agonistas GLP-1/GIP na microbiota intestinal e potencial associação com SIBO},
journal = {Revista ft},
year = {2026},
volume = {30},
number = {158},
pages = {01--25},
doi = {10.69849/7wmx9h50}
}
EUVIMED